Table 1.
Study | Year | Gene | Country | Sample | Results |
---|---|---|---|---|---|
RTK class I | |||||
COOMBS [32] | 1993 | HER2 | UK |
91 tumor tissues 99 control tissues |
Correlation between tumor grade and HER2 up regulation |
SIMON [33] | 2003 | HER2 | Switzerland | 2317 tumor tissues | Correlation between tumor grade and HER2 up regulation |
NADOUSHAN [34] | 2009 | HER2 | Iran | 75 patients | Correlation between tumor grade and HER2 up regulation |
Krüger [35] | 2002 | HER2 | Germany | 138 patients | Correlation between tumor grade and HER2 up regulation |
COOGAN [36] | 2004 | HER2 | USA | 54 patients | Correlation between tumor grade and HER2 up regulation |
LATIF [37] | 2004 | HER2 | UK | 75 patients | Increased HER2 copy number |
LATIF [38] | 2003 | HER2 | UK | 25 patients | Increased HER2 copy number |
FLEISCHMANN [39] | 2011 | HER2 | Switzerland | 150 patients | HER2 amplification was correlated with poor prognosis. |
HANSEL [40] | 2008 | HER2 | USA | 53 patients | HER2 amplification was correlated with high-stage (pT4). |
EISSA [41] | 2005 | HER2 | Egypt | 88 patients | HER2 expression was correlated with lymph node involvement. |
ABDELRAHMAN [42] | 2019 | HER2 | Egypt | 60 patients | HER2 up regulation was correlated RFS and PFS. |
DING [43] | 2015 | HER2 | China | 238 patients | HER2 up regulation was correlated with advanced grade and stage. |
BREYER [44] | 2016 | HER2 | Germany | 355 patients | HER2 up regulation was correlated with advanced grade and stage. |
ARIKAN [45] | 2015 | HER2 | Turkey |
44 patients 40 controls |
HER2 urinary level was correlated with advanced grade. |
KOLLA [46] | 2008 | HER2 | India | 90 patients | HER2 expression was correlated with advanced grade, stage, and lymph node metastasis. |
KOGA [47] | 2011 | HER2 | Japan | 35 patients | HER2 up regulation was correlated with poor prognosis. |
INOUE [48] | 2014 | HER2 | Japan | 201 patients | HER2 up regulation was correlated with CRT resistance. |
SASAKI [49] | 2014 | HER2 | Japan | 171 patients | HER2 up regulation was correlated with grade and recurrence. |
KIM [50] | 2016 | HER2 | South Korea | 6 patients | HER2 protein up regulation and gene amplification |
MEMON [51] | 2004 | HER3, HER4 | Denmark | 88 patients | HER3 and HER4 up regulations were correlated with good prognosis. |
GUNES [52] | 2013 | EGFR, HER2, ErbB3, ErbB4 | Turkey | 40 patients | EGFR and HER2 were down regulated and up regulated respectively. |
Türkeri [53] | 1998 | EGFR | Turkey | 21 patients | EGFR expression was correlated with stage. |
POPOV [54] | 2004 | EGFR | France |
113 patients 10 controls |
EGFR expression was correlated with survival. |
ARFAOUI [55] | 2016 | EGFR | Tunisia |
64 patients 6 controls |
EGFR expression was correlated with grade and stage. |
BERGER [56] | 1987 | EGFR | UK | 31 patients | EGFR expression was correlated with grade and stage. |
KHALED [57] | 2009 | EGFR | Egypt | 59 patients | EGFR expression was correlated with stage and survival. |
LIPPONEN [58] | 1994 | EGFR, HER2 | Finland | 234 patients | EGFR expression was correlated with grade and aneuploidy. |
MEMON [59] | 2006 | EGFR, HER2, HER3, HER4 | Denmark | 88 patients | HER1–4 were correlated with poor prognosis. |
KIM [60] | 2014 | EGFR | Korea | 80 patients | EGFR up regulation was correlated with chemo resistance. |
COLQUHOUN [61] | 2006 | EGFR | UK | 110 patients | EGFR expression was correlated with recurrence. |
Thøgersen [62] | 1999 | EGFR | Denmark | 54 patients | EGFR up regulation was correlated with stage. |
MANSOUR [63] | 2018 | EGFR | Egypt | 58 patients | EGFR up regulation was correlated with poor prognosis. |
Bryan [64] | 2015 | EGFR | UK |
436 patients 60 controls |
EGFR urine levels were correlated with grade and survival. |
CHU [65] | 2013 | EGFR | China |
908 patients 1239 controls |
Polymorphism was correlated with BCa progression. |
MASON [66] | 2009 | EGFR | USA |
857 patients 1191 controls |
Polymorphism was correlated with BCa progression. |
LI [67] | 2015 | HER2, EGFR, VEGFR | USA | 16 patients | EGFR up regulation |
RAJJAYABUN [63, 68] | 2005 | EGFR, HER2 | UK | 58 patients | HER2 and EGFR up regulations |
IMAI [69] | 1995 | EGFR, HER2 | Japan | 30 patients | HER2 and EGFR up regulations were correlated with recurrence. |
LI [70] | 2018 | EGFR, HER2 | China |
56 patients 10 controls |
HER2 and EGFR expressions were correlated with stage. |
KASSOUF [71] | 2008 | EGFR, HER2, ErbB-3, ErbB-4 | Canada | 248 tumors | EGFR and ErbB-4 expressions were correlated with grade and survival. |
RTK class II | |||||
GONZALEZ-ROBIN [72] | 2014 | IGF1R | USA | 100 patients | IGF1R expression was correlated with pT classification. |
ROCHESTER [73] | 2007 | IGF1R | UK |
40 tumor tissues 15 control tissues |
IGF1R expression was correlated with pT classification. |
Metalli [74] | 2010 | IGF1R | USA | 5 patients | IGF1R up regulation |
Iozzo [75] | 2011 | IGF1R | USA | 40 patients | IGF1R up regulation |
RTK class V | |||||
MARZIONI [76] | 2009 | FGFRI, FGFR2 | Italy | 17 patients | FGFRI, FGFR2, and bFGF up regulations |
Dueñas [77] | 2015 | PIK3CA, FGFR3 | Spain | 87 patients | PIK3CA and FGFR3 mutations were correlated with grade and recurrence. |
JUANPERE [78] | 2012 | FGFR3, PIK3CA, KRAS, AKT1, | Spain | 88 patients | Mutations were correlated with grade. |
KOMPIER [79] | 2010 | FGFR3, HRAS, KRAS, NRAS, PIK3CA | Netherlands | 257 patients | Mutations were correlated with grade. |
PANDITH [80] | 2016 | FGFR3 | India | 65 patients | Mutation was correlated with grade and stage. |
BERTZ [81] | 2014 | FGFR3 | Germany | 61 patients | Mutation was correlated with prognosis and recurrence. |
BILLEREY [82] | 2013 | FGFR3 | France | 132 patients | FGFR3 mutation was correlated with pT classification. |
VAN OERS [83] | 2007 | FGFR3 | Germany | 255 patients | FGFR3 mutation was correlated with grade. |
VAN OERS [84] | 2009 | FGFR3 | UK, France | 280 patients | FGFR3 mutation was correlated with pT classification and prognosis. |
MHAWECH-FAUCEGLIA [85] | 2006 | FGFR3 | USA | 254 patients | FGFR3 up regulation was correlated with grade and stage. |
BREYER [86] | 2018 | FGFR3 | Germany | 296 patients | FGFR3 expression was correlated with grade. |
BODOOR [87] | 2010 | FGFR3 | Jordan | 130 patients | FGFR3 expression was correlated with grade and stage. |
PEDREGOSA [88] | 2017 | FGFR3 | Spain | 55 patients | FGFR3 expression was correlated with tumor size and survival. |
YANG [89] | 2018 | FGFR3 | China | 52 patients | FGFR3 mutation was associated with better prognosis. |
ABDUL-MAKSOUD [90] | 2016 | FGFR1 | Egypt |
80 patients 80 controls |
FGFR1 expression was correlated with grade and stage. |
RTK classes of VIII, IX, and XIII | |||||
MCNEIL [91] | 2014 | c-MET | USA | 183 patients | Urinary MET levels were correlated with muscle invasion. |
KIM [92] | 2015 | c-MET, AXL, PDGFR | Korea |
165 patients 34 controls |
Expressions were correlated with prognosis. |
CHENG [93] | 2005 | c-MET | Taiwan | 183 patients | RON and MET expressions were correlated with survival. |
Abraham [94] | 2006 | EphA2 | USA |
64 tumor tissues 13 normal tissues |
EphA2 expression was correlated with tumor stage. |
XIA [95] | 2006 | EphB4 | USA | 15 patients | EphB4 up regulation |
Xie [96] | 2017 | DDR1 | China | 44 patients | DDR1 expression was correlated with poor prognosis. |
Tsai [97] | 2016 | DDR2 | Taiwan | 340 patients | DDR2 up regulation was correlated with poor prognosis, infiltrative pattern, higher grade, advanced T stage, and metastatic status. |
Other tyrosine kinase receptors | |||||
LAI [98] | 2010 | BDNF, TrkB | Taiwan | 116 tumor tissues | BDNF and TrkB up regulations |
PAN [99] | 2005 | c-KIT | USA | 52 patients | c-KIT up regulation |
SHAMS [100] | 2013 | c-KIT | Egypt | 120 patients | c-KIT up regulation |
Non-receptor tyrosine kinases | |||||
ASAI [101] | 2018 | FES | Japan | 203 patients | FES up regulation was correlated with poor prognosis. |
NOMURA [102] | 2015 | DYRK2 | Japan | 44 patients | DYRK2 expression was correlated with survival. |
GUO [103] | 2011 | ETK | USA | 233 patients | ETK up regulation was correlated with grade and prognosis. |